Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen
Valeria Sansone(University of Milan), Adele D’Amico(Bambino Gesù Children's Hospital), Vincenzo Di Bella(Martin University), Giorgia Coratti, Rita De Sanctis(Humanitas University), Simone Morando, Sonia Messina(University of Messina), Eugenio Mercuri(Università Cattolica del Sacro Cuore), Maria Carmela Pera(Università Cattolica del Sacro Cuore), Marika Pane(Università Cattolica del Sacro Cuore), Marina Pedemonte(Istituto Giannina Gaslini), Francesca Salmin(University of Milan), Emilio Albamonte(University of Milan), Laura Antonaci, Claudio Bruno(Istituto Giannina Gaslini), Maria Sframeli(Martin University), Alice Pirola(University of Milan), A. Frongia(Università Cattolica del Sacro Cuore)
Cited by 19
Related Papers
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
|Neuromuscular Disorders|2019|636
Longitudinal effect of eteplirsen versus historical control on ambulation in <scp>D</scp> uchenne muscular dystrophy
|Annals of Neurology|2015|502
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
|The Lancet Oncology|2017|493
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
|The Lancet Neurology|2021|260
Leiomodin-3 dysfunction results in thin filament disorganization and nemaline myopathy
|Journal of Clinical Investigation|2014|204